Title: Aarkstore - Cystic Fibrosis - Pipeline Review, H2 2014
1Cystic Fibrosis - Pipeline Review, H2 2014
Category Pharmaceuticals Healthcare
- Browse Complete Report -
- http//www.aarkstore.com/pharmaceuticals-healthcar
e/63083/cystic-fibrosis-pipeline-review
2Cystic Fibrosis - Pipeline Review, H2 2014
3Summary
- Global Markets Directs, Cystic Fibrosis -
Pipeline Review, H2 2014, provides an overview
of the Cystic Fibrosiss therapeutic
pipeline.This report provides comprehensive
information on the therapeutic development for
Cystic Fibrosis, complete with comparative
analysis at various stages, therapeutics
assessment by drug target, mechanism of action
(MoA), route of administration (RoA) and molecule
type, along with latest updates, and featured
news and press releases. It also reviews key
players involved in the therapeutic development
for Cystic Fibrosis and special features on
late-stage and discontinued projects. - Global Markets Directs report features
investigational drugs from across globe covering
over 20 therapy areas and nearly 3,000
indications. The report is built using data and
information sourced from Global Markets Directs
proprietary databases, Company/University
websites, SEC filings, investor presentations and
featured press releases from company/university
sites and industry-specific third party sources,
put together by Global Markets Directs team.
4Summary
- Drug profiles/records featured in the report
undergoes periodic updation following a stringent
set of processes that ensures that all the
profiles are updated with the latest set of
information. Additionally, processes including
live news deals tracking, browser based
alert-box and clinical trials registries tracking
ensure that the most recent developments are
captured on a real time basis.The report
enhances decision making capabilities and help to
create effective counter strategies to gain
competitive advantage. It strengthens RD
pipelines by identifying new targets and MOAs to
produce first-in-class and best-in-class
products.Note Certain sections in the report
may be removed or altered based on the
availability and relevance of data for the
indicated disease.
5Scope
- - The report provides a snapshot of the global
therapeutic landscape of Cystic Fibrosis- The
report reviews key pipeline products under drug
profile section which includes, product
description, MoA and RD brief, licensing and
collaboration details other developmental
activities - The report reviews key players
involved in the therapeutics development for
Cystic Fibrosis and enlists all their major and
minor projects- The report summarizes all the
dormant and discontinued pipeline projects - A
review of the Cystic Fibrosis products under
development by companies and universities/research
institutes based on information derived from
company and industry-specific sources- Pipeline
products coverage based on various stages of
development ranging from pre-registration till
discovery and undisclosed stages- A detailed
assessment of monotherapy and combination therapy
pipeline projects- Coverage of the Cystic
Fibrosis pipeline on the basis of target, MoA,
route of administration and molecule type-
Latest news and deals relating related to
pipeline products
6Reasons to buy
- - Provides strategically significant competitor
information, analysis, and insights to formulate
effective RD development strategies- Identify
emerging players with potentially strong product
portfolio and create effective counter-strategies
to gain competitive advantage- Develop strategic
initiatives by understanding the focus areas of
leading companies- Identify and understand
important and diverse types of therapeutics under
development for Cystic Fibrosis- Plan mergers
and acquisitions effectively by identifying key
players of the most promising pipeline- Devise
corrective measures for pipeline projects by
understanding Cystic Fibrosis pipeline depth and
focus of Indication therapeutics- Develop and
design in-licensing and out-licensing strategies
by identifying prospective partners with the most
attractive projects to enhance and expand
business potential and scope- Modify the
therapeutic portfolio by identifying discontinued
projects and understanding the factors that drove
them from pipeline
7Table of Content
List of Tables 7List of Figures 9Introduction
10Global Markets Direct Report Coverage
10Cystic Fibrosis Overview 11Therapeutics
Development 12Pipeline Products for Cystic
Fibrosis - Overview 12Pipeline Products for
Cystic Fibrosis - Comparative Analysis 13Cystic
Fibrosis - Therapeutics under Development by
Companies 14Cystic Fibrosis - Therapeutics under
Investigation by Universities/Institutes
18Cystic Fibrosis - Pipeline Products Glance
20Late Stage Products 20Clinical Stage Products
21Early Stage Products 22
8Table of Content
Unknown Stage Products 23Cystic Fibrosis -
Products under Development by Companies 24Cystic
Fibrosis - Products under Investigation by
Universities/Institutes 29Cystic Fibrosis -
Companies Involved in Therapeutics Development
30Alaxia SAS 30AlgiPharma AS 31Bayer AG
32Beech Tree Labs, Inc. 33Carolus Therapeutics,
Inc. 34Celsus Therapeutics Plc 35Celtaxsys,
Inc. 36Chiesi Farmaceutici SpA 37Cilian AG
38Concert Pharmaceuticals, Inc. 39Corbus
pharmaceuticals, Inc. 40
9List Of Tables
- Number of Products under Development for Cystic
Fibrosis, H2 2014 18Number of Products under
Development for Cystic Fibrosis - Comparative
Analysis, H2 2014 19Number of Products under
Development by Companies, H2 2014 20Number of
Products under Development by Companies, H2 2014
(Contd..2) 22Number of Products under
Development by Companies, H2 2014 (Contd..3)
23Number of Products under Investigation by
Universities/Institutes, H2 2014 25Comparative
Analysis by Late Stage Development, H2 2014
26Comparative Analysis by Clinical Stage
Development, H2 2014 27Comparative Analysis by
Early Stage Development, H2 2014 28Comparative
Analysis by Unknown Stage Development, H2 2014
29Products under Development by Companies, H2
2014 30Products under Development by Companies,
H2 2014 (Contd..1) 31
10List Of Tables
- Products under Development by Companies, H2 2014
(Contd..2) 32Products under Development by
Companies, H2 2014 (Contd..3) 33Products under
Development by Companies, H2 2014 (Contd..4)
34Products under Investigation by
Universities/Institutes, H2 2014 35Cystic
Fibrosis - Pipeline by Alaxia SAS, H2 2014
36Cystic Fibrosis - Pipeline by AlgiPharma AS,
H2 2014 37Cystic Fibrosis - Pipeline by Bayer
AG, H2 2014 38Cystic Fibrosis - Pipeline by
Beech Tree Labs, Inc., H2 2014 39Cystic Fibrosis
- Pipeline by Carolus Therapeutics, Inc., H2 2014
40Cystic Fibrosis - Pipeline by Celsus
Therapeutics Plc, H2 2014 41Cystic Fibrosis -
Pipeline by Celtaxsys, Inc., H2 2014 42Cystic
Fibrosis - Pipeline by Chiesi Farmaceutici SpA,
H2 2014 43Cystic Fibrosis - Pipeline by Cilian
AG, H2 2014 44 - Cystic Fibrosis - Pipeline by Concert
Pharmaceuticals, Inc., H2 2014 Cystic Fibrosis -
Pipeline by Corbus pharmaceuticals, Inc., H2 2014
Cystic Fibrosis - Pipeline by Cubist
Pharmaceuticals, Inc., H2 2014 Cystic Fibrosis -
Pipeline by DiscoveryBiomed, Inc., H2 2014 48
11List of Figures
- Number of Products under Development for Cystic
Fibrosis, H2 2014 18Number of Products under
Development for Cystic Fibrosis - Comparative
Analysis, H2 2014 19Number of Products under
Development by Companies, H2 2014 20Number of
Products under Investigation by
Universities/Institutes, H2 2014 24Comparative
Analysis by Late Stage Development, H2 2014
26Comparative Analysis by Clinical Stage
Development, H2 2014 27Comparative Analysis by
Early Stage Products, H2 2014 28Assessment by
Monotherapy Products, H2 2014 86Number of
Products by Top 10 Targets, H2 2014 88Number of
Products by Stage and Top 10 Targets, H2 2014
88Number of Products by Top 10 Mechanism of
Actions, H2 2014 91Number of Products by Stage
and Top 10 Mechanism of Actions, H2 2014
91Number of Products by Top 10 Routes of
Administration, H2 2014 94
12Related Reports
- Global Neurosurgery Market 2015-2019
- BrainStorm Cell Therapeutics Inc. (BCLI) -
Financial and Strategic SWOT Analysis Review - Ampio Pharmaceuticals, Inc. (AMPE) - Financial
and Strategic SWOT Analysis Review - MiMedx Group, Inc (MDXG) - Financial and
Strategic SWOT Analysis Review - Threshold Pharmaceuticals, Inc. (THLD) -
Financial and Strategic SWOT Analysis Review
13Related Reports
- MEI Pharma, Inc. (MEIP) - Financial and Strategic
SWOT Analysis Review - Titan Pharmaceuticals, Inc. (TTNP) - Financial
and Strategic SWOT Analysis Review - RedHill Biopharma Ltd. (RDHL) - Financial and
Strategic SWOT Analysis Review - Pharmaceuticals Healthcare Market Research
Reports
14- Cystic Fibrosis - Pipeline Review, H2 2014
- Published Oct 2014 267 Pages
- Cystic Fibrosis - Pipeline Review, H2 2014 report
features investigational drugs from across globe
covering over 20 therapy areas and nearly 3,000
indications.
Price
Format Price
PDF 2000
Site Licence 4000
Enterprise Wide Licence 6000
15Contact Us
Office Office No. - 809, 8th Floor,B-Wing,
Mahaavir Icon, Plot No.- 89 90,
Sector-15,CBD-Belapur, Navi Mumbai
400614, Maharashtra, India. Telefax No 91 22
4127 6660 24/7 Online Support 91
9987295242 General Inquiries 91 - 22 2756 4953
- You Can Visit http//www.aarkstore.com
- OR Mail us at contact_at_aarkstore.com
- Blog
- http//www.aarkstore.com/blog/
- Conference
- http//conference.aarkstore.com/
- News
- http//www.aarkstore.com/news